UnknownPhase 3

Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.

Italy362 participantsStarted 2020-01-14

Plain-language summary

The aim of our study will be to assess in an open-label, multicenter, randomized controlled trial whether a tailored therapy guided by a non-invasive antibiotic susceptibility test on stool samples achieves higher Helicobacter eradication rates than an empiric antibiotic regimen. For this purpose, consecutive patients with dyspeptic symptoms, diagnosis of Helicobacter pylori infection and naïve to eradicating treatments will be allocated to either of the two intervention arms.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * presence of dyspeptic symptoms, according to Rome IV criteria; * Helicobacter pylori infection diagnosis by the positivity of at least 2 out of 4 diagnostic tests (i.e. histology, rapid urease test, urea breath test, and serology); * naive to Helicobacter pylori treatment; * written informed consent. Exclusion Criteria: * previous Helicobacter pylori treatment; * diagnosis of gastric cancer or other diseases requiring surgery; * contraindications to upper endoscopy; * chronic diarrhea; * known allergy to any drugs used in the intervention and control arm.

What they're measuring

Eradication rate

Timeframe: 30 days

Trial details

NCT IDNCT04107194

SponsorUniversity of Bari

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-14

Contact for this trial

Michele Barone, Prof.

+39 3477157666 michele.barone@uniba.it

View on ClinicalTrials.gov More Helicobacter Pylori Infection trials